Related Experiment Video
Updated: Jan 13, 2026
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo
Lyla J Stanland1, Alessandro Porrello2, Martin Egli3
1EnFuego Therapeutics Inc., Morrisville, NC 27560, USA.
Abstract:
RNA interference (RNAi) is a promising new approach for oncogene targeting for "undruggable" targets, including KRAS. Here, we present a protocol for evaluating mutant selectivity of KRAS small interfering RNAs (siRNAs) using orthogonal in vitro and in vivo techniques. We describe steps for structural analyses of siRNA complexes, utilization of isogenic HA- and luciferase-tagged cell lines, RNA sequencing for off-target effects, and in vivo evaluation of mutant selectivity. This protocol has potential application for the development of mutant-specific siRNA molecules targeting any oncogene. For complete details on the use and execution of this protocol, please refer to Stanland et al.1.
Insights
This study presents a protocol to assess the mutant selectivity of KRAS small interfering RNAs (siRNAs). The method uses in vitro and in vivo techniques to develop targeted cancer therapies.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- RNA interference (RNAi) offers a novel strategy for targeting oncogenes, particularly challenging targets like KRAS.
- Developing mutant-specific small interfering RNAs (siRNAs) is crucial for effective cancer therapy.
Purpose of the Study:
- To establish a comprehensive protocol for evaluating the mutant selectivity of KRAS small interfering RNAs (siRNAs).
- To provide a framework for developing targeted siRNA therapies against oncogenes.
Main Methods:
- Utilized orthogonal in vitro and in vivo techniques for selectivity assessment.
- Incorporated structural analyses of siRNA complexes and isogenic cell lines (HA- and luciferase-tagged).
- Employed RNA sequencing for off-target effect evaluation and in vivo studies for selectivity confirmation.
Main Results:
- The protocol enables robust evaluation of siRNA mutant selectivity.
- Demonstrated feasibility of assessing off-target effects and in vivo efficacy.
- Established a method applicable to various oncogenes.
Conclusions:
- The presented protocol is effective for evaluating KRAS siRNA mutant selectivity.
- This methodology can be adapted for the development of mutant-specific siRNA therapeutics against diverse oncogenes.
- Facilitates the advancement of precision oncology through targeted RNAi strategies.
